Arcutis Biotherapeutics (ARQT) Stock Analysis & AI Equity Report
Arcutis Biotherapeutics (ARQT) overview
Arcutis Biotherapeutics (ARQT) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 376m and operating profit of USD -12.2m; the year-end share price was 29.04 USD and market capitalisation was USD 3,582m. Arcutis Biotherapeutics is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arcutis Biotherapeutics's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Arcutis Biotherapeutics
Arcutis Biotherapeutics develops and commercializes treatments for dermatological diseases, focusing on immune-mediated skin conditions. Its portfolio includes topical ZORYVE products: creams approved for plaque psoriasis and atopic dermatitis, and foam approved for seborrheic dermatitis and plaque psoriasis. The company serves patients through commercial sales in the United States and Canada and has a promotion agreement for U.S. marketing to primary care providers.
Generate the Arcutis Biotherapeutics report
Arcutis Biotherapeutics is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Arcutis Biotherapeutics and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Arcutis Biotherapeutics
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.